Business Context and Reporting Period
National Research Corporation (NRC Health) filed a Form 8-K on March 4, 2026, to disclose a material business update. The filing serves as a Regulation FD disclosure regarding a significant milestone in the company's contract portfolio.
Key Financial Metrics
- Total Recurring Contract Value (TRCV): Surpassed $152 million as of March 4, 2026.
- Revenue, Profit, Cash Flow, Margins, Debt, Liquidity: The filing text does not provide clear values for these specific financial metrics.
Material Changes
The company reported that its TRCV reached an all-time high of over $152 million. This represents a material positive development in the company's recurring revenue base compared to prior periods, though specific prior period values are not detailed in this filing.
Guidance, Outlook, and Risks
The filing incorporates a press release (Exhibit 99.1) containing forward-looking statements based on management's current beliefs. The company explicitly notes that actual results may differ due to significant risks and uncertainties. Investors are directed to the press release and other SEC filings for detailed risk factors and contingencies.
Investor Verification Checklist
- Verify the definition and calculation methodology of "Total Recurring Contract Value" (TRCV) in the attached press release (Exhibit 99.1).
- Confirm the conversion rate of TRCV to actual recognized revenue in upcoming quarterly reports.
- Review the specific risk factors outlined in the press release that could impact the realization of this contract value.
- Check subsequent filings for any updates on the $152 million milestone or changes in contract terms.